Company Valuation: IMPACT Therapeutics, Inc

Data adjusted to current consolidation scope
Fiscal Period: December 2026 2027 2028
Market Cap 1 3,399 - -
Change - - -
Enterprise Value (EV) 1 2,582 2,393 2,271
Change - -7.33% -5.12%
P/E - - -
PBR - - -
PEG - - -
Capitalization / Revenue 12.8x 5.4x 4.91x
EV / Revenue 9.75x 3.8x 3.28x
EV / EBITDA -18.4x 19.7x 35.7x
EV / EBIT -17.9x 20.2x 37.9x
EV / FCF - - -
FCF Yield - - -
Dividend per Share 2 - - -
Rate of return - - -
EPS 2 - - -
Distribution rate - - -
Net sales 1 264.8 629.6 692
EBITDA 1 -140.7 121.4 63.66
EBIT 1 -144.2 118.4 59.97
Net income - - -
Net Debt 1 -816.4 -1,006 -1,128
Reference price 2 12.03 12.03 12.03
Nbr of stocks (in thousands) 282,462 - -
Announcement Date - - -
1CNY in Million2CNY
Estimates

P/E, Detailed evolution



P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
- 11.78x-22.16x - 501M
20.87x7.45x14.96x1.42% 71.53B
31.24x9x28.05x0.04% 60.12B
34.13x6.11x18.31x0.95% 48.85B
34.64x3.34x14.41x-.--% 44.28B
-21.08x228.26x-22.72x-.--% 43.83B
47.85x5.53x30.37x-.--% 41.53B
27.07x7.8x20.09x0.42% 30.13B
32.39x6.91x17.94x-.--% 27.98B
-70.94x13.62x-69.42x-.--% 25.25B
Average 15.13x 29.98x 2.98x 0.32% 39.4B
Weighted average by Cap. 19.23x 31.81x 9.89x 0.42%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA



Year-on-year evolution of the Yield

  1. Stock Market
  2. Stocks
  3. 7630 Stock
  4. Valuation IMPACT Therapeutics, Inc